Discussion on:
Message 3 of 1
@Loverock Davidson - I would think that this type of model would benefit the big pharmaceutical companies. Aren't most of their costs sunk into R&D? By having a shared, open data model, you can essentially reduce the R&D costs and spur faster product development through competition.
The best of ZDNet, delivered
ZDNet Newsletters
Get the best of ZDNet delivered straight to your inbox
